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Abstract: Exposure to untreated gestational diabetes mellitus (GDM) in utero increases the risk
of obesity and type 2 diabetes in adulthood, and increased adiposity in GDM-exposed infants is
suggested as a plausible mediator of this increased risk of later-life metabolic disorders. Evidence is
equivocal regarding the impact of good glycaemic control in GDM mothers on infant adiposity at birth.
We systematically reviewed studies reporting fat mass (FM), percent fat mass (%FM) and skinfold
thicknesses (SFT) at birth in infants of mothers with GDM controlled with therapeutic interventions
(IGDMtr). While treating GDM lowered FM in newborns compared to no treatment, there was no
difference in FM and SFT according to the type of treatment (insulin, metformin, glyburide). IGDMtr
had higher overall adiposity (mean difference, 95% confidence interval) measured with FM (68.46 g,
29.91 to 107.01) and %FM (1.98%, 0.54 to 3.42) but similar subcutaneous adiposity measured with
SFT, compared to infants exposed to normal glucose tolerance (INGT). This suggests that IGDMtr
may be characterised by excess fat accrual in internal adipose tissue. Given that intra-abdominal
adiposity is a major risk factor for metabolic disorders, future studies should distinguish adipose
tissue distribution of IGDMtr and INGT.
Keywords: gestational diabetes mellitus; treatment; adiposity; fat mass; skinfold thickness; new-
borns; infants
1. Introduction
The prevalence of gestational diabetes mellitus (GDM) is rising globally, affecting
up to 38% of pregnancies in some populations [1]. As well as causing complications
during pregnancy and delivery including macrosomia, shoulder dystocia and preterm
birth, exposure to GDM in utero places offspring at an increased risk of obesity and type 2
diabetes in later life [2,3]. The mechanisms associated with this increased risk of obesity and
type 2 diabetes are not well understood; however, increased adiposity during foetal growth
has been suggested as a potential mediator [4]. The Pedersen hypothesis [5] suggests that,
as glucose freely crosses the placenta, maternal hyperglycaemia in diabetic pregnancies
leads to foetal hyperinsulinaemia, causing accelerated foetal uptake of glucose (foetal
glucose steal phenomenon) and deposition of excess foetal adipose tissue [6]. The impact
of GDM on adipose tissue growth in the foetus can be identified with adiposity measures at
birth, for example, fat mass (FM), percent fat mass (%FM) and skinfold thickness (SFT) [7].
Diagnosis and management of GDM continue to be controversial. The earlier defi-
nition of GDM, i.e., “any degree of glucose intolerance that occurs or is first diagnosed
during pregnancy” [8], was used for many years and enabled a uniform approach to
the detection of GDM. However, the classification of women with unrecognized overt
diabetes as GDM and providing treatments accordingly may not be effective because risks
associated with type 1 and type 2 diabetes are greater than GDM [9]. In the latest clinical
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practice recommendations by the American Diabetes Association [10], GDM is defined as
“glucose intolerance first diagnosed during the second or third trimester of pregnancy in
women without overt diabetes prior to pregnancy, which resolves postnatally”, and this
involves risk-based screening for type 2 diabetes or prediabetes at their initial prenatal
visit. Nonetheless, different criteria are currently being used worldwide to diagnose GDM.
A landmark change in these diagnostic thresholds occurred when the Hyperglycaemia
and Adverse Pregnancy Outcome (HAPO) study [11] demonstrated a positive linear as-
sociation between increasing levels of plasma glucose and adverse pregnancy outcomes
and subsequently, lowered thresholds for screening GDM. These new diagnostic thresh-
olds (fasting plasma glucose 5.1–6.9 mmol/L, 1-h plasma glucose ≥ 10.0 mmol/L or 2-h
8.5–11.0 mmol/L) were promulgated by the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) in 2010 and by the World Health Organisation (WHO)
in 2013, and this enabled detection of more GDM cases [12].
Awareness of the adverse outcomes associated with GDM has been a driver for sub-
stantial improvements in perinatal care for pregnant women with GDM in recent years [13].
The first-line treatment for GDM involves lifestyle changes, e.g., modified diet and in-
creased physical activity, and nearly two-thirds of women can achieve glycaemic targets
with this approach [14]. When blood glucose levels are not adequately controlled with
modified lifestyle alone, supplementary pharmacological treatments such as metformin,
glyburide or insulin are added to the therapeutic regimen [15]. Glycaemic control in GDM
women using modified dietary interventions alone has resulted in lower birth weights
and less macrosomia [16], despite the high heterogeneity in diet observed among different
populations [17]. Similarly, using pharmaceutical interventions along with or without
lifestyle changes has resulted in reduced risk of macrosomia [18] and has prevented GDM-
associated adverse health conditions in neonates [19]. Nevertheless, the effect of GDM
treatments on neonatal adiposity is understudied, and the evidence for whether good gly-
caemic control in GDM can normalise foetal adiposity is contradictory [20–22]. To ascertain
the impact of glycaemic control in GDM on infant adiposity at birth, we systematically
reviewed studies reporting adiposity in newborns of mothers with GDM controlled with
therapeutic interventions.
2. Materials and Methods
This work was conducted following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [23]. Our protocol is registered in
PROSPERO (CRD42020175338).
2.1. Search Strategy
Electronic searches were conducted in three stages with the assistance of a Research
Librarian at the University of Tasmania, Australia. First, a limited search was undertaken
in Medline and Scopus, using search terms: “gestational diabetes”, “body composition”
and “infants”. The title, abstract and index terms of the retrieved articles were scanned
to build a keyword list. In the second step, a broader search was conducted (March 2020),
using the identified terms in MEDLINE in Ovid, Embase, CINHAL, PubMed and Web of
Science databases, limiting the results to studies published in “English” language, “human”
species and “infants” age group. The search strategy for MEDLINE is shown in Figure S1,
and a similar approach was used in other databases. Finally, we manually scanned the
reference lists of included articles, relevant reviews, and citations to identify any additional
studies. Hand searches were not conducted for any specific journal, and we did not trace
any grey literature.
2.2. Eligibility Criteria
We included all study types reporting adiposity in infants exposed to GDM. Inclusion
criteria were: (1) data collected at birth or <1-month infants’ age; (2) availability of infant
adiposity measure(s); i.e., fat mass (FM), percent fat mass (%FM) or skinfold thickness (SFT);
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and (3) availability of information regarding what therapeutic measures were undertaken to
control GDM. Exclusion criteria were (1) examination of maternal glycaemia as a continuous
variable; (2) assessment of only foetal measurements (e.g., ultrasound scans); (3) merging
of data for GDM exposed infants with pregestational diabetes-exposed infants; (4) full
report of the study not published in English; and (5) review articles, protocol papers and
conference abstracts. When there were multiple publications from the same sample of
study participants, we only included the paper that presented the most appropriate data
for the purpose of this review.
2.3. Study Selection
The results emanating from database searches were imported into the Covidence
software® [24]. After removing duplicates, the search outputs were independently re-
viewed at the title and abstract level by M.P.H. and K.D.K.A./J.M.B. to find potentially
eligible articles. These articles were screened at the full-text level by the same reviewers to
determine the eligibility of the papers for data extraction.
2.4. Quality Assessment
The methodological quality of the selected studies was assessed by two reviewers
(M.P.H. and J.M.B) using the Evidence Project risk of bias tool. This tool is appropriate for
assessing study rigour for both randomised and non-randomised intervention studies. The
Evidence Project risk of bias tool includes eight items: (1) cohort, (2) control or comparison
group, (3) pre-post intervention data, (4) random assignment of participants to the inter-
vention, (5) random selection of participants for assessment, (6) follow-up rate of 80% or
more, (7) comparison groups equivalent on sociodemographics, and (8) comparison groups
equivalent at baseline on outcome measures [25]. For criterion 7, we considered infant sex
and ethnicity as the relevant sociodemographic characteristics. If authors reported that
study arms were equivalent on only one sociodemographic variable, we considered the
meeting of the criterion as “Partial”. Additionally, if the study arms were not equivalent on
at least one sociodemographic variable, we considered that the criterion was not met. Any
disagreements between the two reviewers regarding the inclusion of studies and quality
assessment were resolved by discussion and consensus.
2.5. Data Extraction
A pre-designed data collection form was used to extract information from each paper.
This information included: (1) study characteristics (author, year, design, time period
of data collection, state/country of the study, inclusion and exclusion criteria), (2) study
groups (sample size, male%), (3) method(s) (GDM screening/diagnostic criteria, treatments
to control GDM, target blood glucose level, degree of glycaemic control, body composition
measurement technique) and (4) outcomes (FM, %FM, SFT).
2.6. Data Analysis
For the purpose of data synthesis, the included studies were categorised according
to comparison groups: (1) ‘treated’ GDM vs. ‘untreated’ GDM; (2) different treatment
regimens for GDM and, (3) treated GDM vs. normal glucose tolerance (NGT). When
blood glucose levels of GDM mothers were controlled with any form of therapeutic in-
tervention (including lifestyle modification and/or pharmaceutical interventions), they
were considered as ‘treated’, and usual antenatal care without any specific treatment for
GDM was considered as ‘untreated’. When an adequate number of studies were available,
meta-analyses were performed with the inverse variance statistical method and random
effects analysis model (RevMan version: 5.4.0) [26]. Mean difference at a 95% confidence
interval was used to combine the results. Forest plots were used to demonstrate the
outcomes. Heterogeneity between the studies in meta-analyses was determined with a
Chi2 test on the Q statistic (variance of the observed effect sizes in the meta-analysis),
Tau2 (between-study variance of the true effect sizes) and I2 (proportion of the observed
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variation in the effect size due to differences in the true underlying effect sizes, as opposed
to sampling error). An alpha level <0.05 was considered statistically significant. Potential
sources of heterogeneity, i.e., level of glycaemic control in GDM mothers, any advances in
the effectiveness of treatments for GDM in ‘recent’ years (defined as study data collection
occurred during or after 2010: referred as post-2010) compared to ‘pre-2010’ (defined as
study data collection occurred before 2010), GDM diagnosis criteria and body composition
assessment technique, were investigated with subgroup analyses. Sensitivity testing was
performed with ‘leave-one-out’ testing.
3. Results
3.1. Study Selection
Of the 1072 references identified through database searching, 19 matched inclusion-
exclusion criteria (Figure 1). An additional six papers were identified through a review of
reference lists, relevant reviews, and forward citations. In total, 25 studies [7,20–22,27–47]
were included in the systematic review, of which 17 [7,20–22,27–29,31,33,37–39,41–45] were
included in the meta-analysis.
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3.2. Description of the Studies
The selected references included three randomised clinical trials [34–36], 15 cohort
studies [7,21,27,29–31,37,38,41–47], 3 case-control studies [20,33,39,42] and 4 cross-sectional
studies [22,28,32,40]. The included studies were published between 1980 and 2020, and
from 12 different countries, i.e., the United States [7,28,29,31,35,36,40], Australia [21,22,45],
New Zealand [30,33], Australia and New Zealand [34], Germany [37,38,41], Sweden [20,44],
China [32], France [43], Italy [27], Malaysia [47], Spain [39], the United Kingdom [46] and
Turkey [42]. Sample sizes varied from 25 to 1000 (Table 1).
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Table 1. Characteristics and findings of the studies.
First Author, Year, Study
Design, Time of Data
Collection, Location
Study Groups n
(Males%) GDM Identification/Definition Treatment(s)
Target Blood Glucose Levels (BGLs)










Bethesda, MD, USA [36]
Control = 473
Treatment = 485
At 24th and 30th weeks using 4th
International workshop conference
criteria
Diet therapy (n = 427)
and insulin (n = 36)




Good glycaemic control achieved
Birth
FM was calculated as




FM: Lower in treatment group
(427 ± 198 vs. 464 ± 222, p = 0.003)
(2) Different treatment regimens for GDM

















Targeted fasting glucose >5.5
mmol/L and/or 2-h post-prandial
glucose >7.0 mmol/L
<24 h Subscapular SFT: Not significantly different subscapular5.4 (4.8–7.0) vs. 6.8 (5.0–7.9)
Rowan, 2008
randomised, open-label trial












Aimed for the capillary glucose
levels recommended by the ADIPS
(after an overnight fast, <5.5
mmol/L; 2-h post-prandial level,
<7.0 mmol/L
<48 h Triceps and subscapular
SFT: Metformin group not significantly different from
insulin group
triceps (5.2 ± 1.6 vs. 5.1 ± 1.2, p = 0.30)
subscapular (5.2 ± 1.5 vs. 5.2 ± 1.3, p = 0.60)




Pregnancy Diabetes Clinic in
Cleveland
Ohio, USA [7]
NGT = 220 (54%)
GDM = 195 (51%)
National Diabetes Data Group
criteria
Diet only = 128
Diet + insulin = 67
Targeted fasting
glucose >5.5 mmol/L and/or 2-h
post-prandial glucose >6.7 mmol/L;
Women maintained glucose values
within the target range with diet and
exercise (66%), plus insulin (34%)
<72 h TOBEC
FM: Higher in diet + insulin group (492 ± 215 vs.
407 ± 196, p = 0.006)
%FM: Higher in diet + insulin











Participants with a glucose level of
>7.5 mmol/L had a 3-h 100-g OGTT
Insulin = 41
Glyburide = 41
Targeted fasting glucose >5.5
mmol/L and/or 2-h post-prandial
glucose >6.7 mmol/L.
Post-prandial dinner glucose was





and anterior thigh SFT
(individual and sum given)
FM: Insulin group not significantly different from
glyburide group
(370 ± 167 vs. 473 ± 278, p = 0.06)
%FM: Insulin group not significantly different from
glyburide group
(11.2 ± 4.2 vs. 12.8 ± 5.7, p = 0.18)
SFT: Insulin group not
significantly different from glyburide group
triceps
(3.9 ± 0.7 vs. 3.9 ± 0.9, p = 0.89),
subscapular
(4.1 ± 1.0 vs. 4.5 ± 1.3, p = 0.10),
suprailiac
(2.1 ± 0.6 vs. 2.1 ± 0.6, p = 0.85) and
thigh
(5.1 ± 1.2 vs. 5.4 ± 1.7, p = 0.28)
(3) Treated GDM vs. NGT ‡ IGDMtr compared to INGT




AGA NGT = 20
LGA NGT = 20
AGA GDM = 13
O’Sullivan and
Mahan criteria Dietary control ‘Well-managed GDM’ <72 h Triceps
Not significantly different
triceps compared to AGA NGT group (5.0 ± 1.1 vs.
4.3 ± 0.8, p > 0.05) and LGA NGT group (5.0 ± 1.1 vs.
6.2 ± 2.0, p = 0.058)
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Table 1. Cont.
First Author, Year, Study
Design, Time of Data
Collection, Location
Study Groups n
(Males%) GDM Identification/Definition Treatment(s)
Target Blood Glucose Levels (BGLs)










Women and Infants’ hospital,
Rhode Island [29]
AGA NGT = 69
AGA GDM = 62
LGA GDM = 57
LGA NGT = 74
Carpenter and
Coustan criteria
Diet only = 385
Diet + insulin = 34
Diet includes 45–50%
carbohydrates, 25%
protein, and 25% fat.
Targeted fasting glucose >5.5
mmol/L and/or 2-h post-prandial
glucose >6.7 mmol/L. The
management team worked with all
mothers to maintain BGL targets




AGA GDM vs. AGA NGT
Not significantly different triceps (3.5 ± 0.9 vs. 3.6 ±
0.8), subscapular (3.9 ± 1.0 vs. 3.9 ± 0.9), abdominal (3.5
± 1.0 vs. 3.7 ± 0.9), suprailiac (3.4 ± 0.9 vs. 3.6 ± 1.0)
and medial calf (4.8 ± 1.1 vs. 5.1 ± 1.1)
LGA GDM vs. LGA NGT
Not significantly different subscapular (5.5 ± 1.5 vs. 5.3
± 1.3), suprailiac (4.9 ± 1.1 vs. 4.5 ± 1.1) and medial calf
(6.7 ± 1.3 vs. 6.3 ± 1.1)
significantly higher triceps (4.7 ± 1.0 vs. 4.5 ± 1.0) and
abdominal (5.3 ± 1.4 vs. 4.9 ± 1.2)
LGA GDM vs. AGA GDM
Significantly higher
subscapular (5.5 ± 1.5 vs. 3.9 ± 1.0), Abdominal (5.3 ±
1.4 vs. 3.5 ± 1.0), suprailiac (4.9 ± 1.1 vs. 3.4 ± 0.9) and
medial calf (6.7 ± 1.3 vs. 4.8 ± 1.1)
Not significantly different
triceps (4.7 ± 1.0 vs. 3.5 ± 0.9)”
Ng, 2004
Cross-sectional
Prince of Wales Hospital
Hong Kong [32]
NGT = 40 (50%)
GDM = 42 (45.5%) ADIPS criteria (1998)
Low-energy diet (1800
kcal/d) Not reported <24 h Triceps and subscapular
SFT:
Not significantly different triceps (4.8(4.2–5.1) vs.
4.7(4.1–5.5)) and subscapular (4.8(4.3–5.3) vs.









Local criteria for diagnosis of GDM
fasting
glucose ≥5.5 mmol/Land/or a
2-h value after a 75 g glucose load
≥9.0 mmol/l
Insulin, usually as lispro
insulin up to
three times daily along with






Target fasting glucose <5.5 mmol/L
and post-prandial readings <6.5
mmol/l.
<24 h Triceps and scapular
SFT:
Significantly higher triceps (5.0 ± 1.2 vs. 4.4 ± 1.0) and











At 24–28 gestational week using






lifestyle management. All of
them (diabetic) have used
insulin therapy.
While the mean HbA1c level of
mothers with gestational diabetes
was 5.9 ± 1.7%, that of the controls
was 5.2 ± 0.33%; there
was no significant
difference. Therefore, mothers with







Significantly higher triceps (3.9 ± 0.7 vs. 3.3 ± 1.1, p =
0.009) and subscapular (3.8 ± 0.8 vs. 3.4 ± 1.2, p = 0.04)
Not significantly different
biceps






Lean NGT = 164
Lean GDM = 41
Obese NGT = 120
Obese GDM = 90
Fasting blood glucose (FBG) in the
first
trimester for women with BMI ≥30
kg/m2 , and a 75 g OGTT between
24–28 weeks regardless of maternal
BMI. Women were also screened for
GDM at
32 weeks by performing a 75 g OGTT,
regardless of maternal BMI.
International
Association of Diabetes and
Pregnancy Study Groups (IADPSG)
criteria
The first line treatment was
dietary intervention with a
standard 1800 kcal daily
meal plan
divided into three meals and
snacks. Insulin
treatment after two weeks of
failed dietary therapy.
Target fasting glucose <5.0 mmol/L
and
post-prandial level <6.7 mmol/L.
<72 h Triceps, biceps, suprailiacand subscapular
SFT:
Normal weight group
Not significantly different sum of SFT (triceps, biceps,
subscapular, suprailiac)
(18.6 ± 3.7 vs. 17.8 ± 3.1, p > 0.05)
Obese group
Not significantly different sum of SFT
(19.9 ± 44 vs. 19.0 ± 3.5, p > 0.05)
J. Clin. Med. 2021, 10, 835 7 of 20
Table 1. Cont.
First Author, Year, Study
Design, Time of Data
Collection, Location
Study Groups n
(Males%) GDM Identification/Definition Treatment(s)
Target Blood Glucose Levels (BGLs)











(additional data provided by
authors)
Earlier GDM = 98
(53%)
Recent GDM = 122
(54%)
Recent NGT = 876
(52%)
At around 28 weeks
using IADPSG criteria
“Earlier” GDM was mostly
treated with diet and
lifestyle
modification, with or
without insulin. 19% of the
‘earlier’ GDM group were
not diagnosed and did not
receive any
treatment.






Not reported <8 days Triceps, subscapular,flank, quadriceps
SFT:
Earlier GDM
Not significantly different sum of SFT (triceps,
subscapular, flank, quadriceps)
(26.0 ± 6.3 vs. 24.6 ± 6.0)
Significantly higher skinfold SDS (0.31 ± 0.85 vs. 0.03 ±
0.86)
Recent GDM
Significantly lower sum of SFT (20.0 ± 3.6 vs. 24.6 ± 6.0)










GDM was defined according to the
clinic’s guidelines, O’Sullivan
criteria.
Treated with diet or diet +
insulin. Not reported <72 h
Left anterior iliac spine, at
the lower angle of the left
scapula, at the middle of the
femur, above the left
quadriceps femoris and at
the




Not significantly different all 4 sites
triceps, 4.6 ± 0.9 vs. 4.8 ± 1.5, p = 0.67
scapular, 4.3 ± 1.41 vs. 4.1 ± 0.97, p = 0.54
iliac, 4.4 ± 1.3 vs. 4.2 ± 1.0, p = 0.45
femur, 5.2 ± 1.8 vs. 4.7 ± 1.4, p = 0.72
(b) Studies that measured body composition






White’s classification, class A
(abnormal glucose tolerance that
reverted to normal
postpartum)
Low-carbohydrate diet Not reported Birth
FM and FM% calculated by





different (553 ± 49 vs. 386 ± 22)
%FM: Significantly higher (17.1 ± 1.7 vs. 12.2 ± 0.5)





Hospital, Tarragona, Spain [39]
NGT = 130 (46.1%)
GDM = 84 (53.2%)
National Diabetes Data Group
criteria were used to define GDM
before 30 weeks
Diet = 48
Diet + insulin = 29
Target fasting glucose values <5.3
mmol/L and or 1-h post-prandial
values <7.8 mmol/L.
GDM women had higher levels of
fasting glucose4.5 ± 0.4 vs. 4.8 ± 0.6
mmol/L
<48 h
FM by Dauncy et al.
equation.
Triceps, biceps, subscapular,












rechts der Isar, Technische
Universität München
Munich, Germany [41]
Lean NGT = 15
(46.7%)
Obese NGT = 13
(61.5%)





Insulin treated = 9
fasting BGL at 3rd
trimester did not
significantly differ
between the groups and was <5.1
mmol/L
1 week
FM by the equations of
Weststrate
and Deurenberg




compared to lean NGT (694 ± 117, vs. 583 ± 139, p <
0.05); Not significantly different compared to obese NGT
(694 ± 117, vs. 660 ± 114, p > 0.05)
SFT:
Significantly higher compared to lean NGT
(21.6 ± 2.4 vs. 18.9 ± 3.1)
Not significantly different compared to obese NGT (21.6
± 2.4 vs. 20.3 ± 2.6)
‘Catalano et al. equation
[50]’
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Table 1. Cont.
First Author, Year, Study
Design, Time of Data
Collection, Location
Study Groups n
(Males%) GDM Identification/Definition Treatment(s)
Target Blood Glucose Levels (BGLs)












2-h capillary whole-blood glucose
concentration above 11 mmol/L,






Daily blood glucose target, HbA1c
3.5–5.3%
Glycaemic control was fairly good,
with mean HbA1c values below the
upper reference limit for healthy
from the 24th to the 36th week of
gestation.
<2 days






(700 ± 200 vs. 500 ± 200, p < 0.01)
%FM:
Significantly higher
(17.0 ± 3.2 vs. 13.5 ± 3.5, p < 0.01)
SFT:
Significantly higher in triceps
(6.6 ± 1.7 vs. 5.3 ± 1.1, p < 0.05) and subscapular (6.0 ±
2.1 vs. 4.8 ± 1.1, p < 0.05)Not significantly different in






NGT = 190 (48.4%)
GDM = 150 (44.0%)
American Diabetes
Association criteria for
measurements in venous plasma.
With respect to lower glucose
concentrations in capillary
compared with venous blood, the
threshold for fasting glucose was
modified into 5.0 mmol/L, while
post
challenge capillary





Insulin therapy given before








AC > 75th percentile
fasting <5.0 mmol/L or
2-h postprandial <11.1 mmol/L
‘Well-controlled’
Maternal serum glucose levels did
not differ
between control subjects and women
with
GDM
<48 h FM by Catalanoet al., equation.
FM:
Significantly higher














GDM were diagnosed by either the
ADIPS guidelines or a universal 75
gm OGTT and revised glucose cut
points as recommended by the WHO.
DIP, was defined as diabetes first
identified in pregnancy, but with
glucose or HbA1c values higher







Not reported <72 h FM by Catalano et al.equation.
FM:
Not significantly different
(11.3 ± 4.2 vs. 11.5 ± 3.7, p = 0.65)
Non-indigenous
Significantly lower




Tertiary antenatal clinic, Kuala
Lumpur, Malaysia [47]











FPG ≥ 5.1 mmol/L and/or 2-h
glucose ≥7.8 mmol/L after a 75 g
OGTT (based on the study centre’s
definition and the Malaysian 2015
Clinical Practice
Guideline








The glycaemic targets for GDM in
the study
centre: fasting 3.5–5.1 mmol/L,
pre-meals 4.0–5.8 mmol/L, 2-h
post-prandial 4.0–6.7 mmol/L.
Well-treated GDM








Not significantly different compared to non-obese NGT
(909 ± 113 vs. 924 ± 149, p > 0.05)Significantly lower
compared to obese NGT (909 ± 113 vs. 973 ± 149, p <
0.05)
SFT:
Significantly lower sum of SFT (flank, triceps,
subscapular) compared to obese NGT (14.2 ± 3.0 vs.
16.1 ± 5.3, p < 0.05)
Not significantly different compared to non-obese NGT






Centre, Cleveland, USA [31]
NGT = 44 (58.8%)
GDM = 34 (59.1%) Carpenter and Coustan criteria
Diet = 23
Diet + insulin = 11 Not reported <48 h
TOBEC
paediatric model HP-2
FM: Significantly higher (480 ± 210 vs. 360 ± 150, p =
0.01)
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Table 1. Cont.
First Author, Year, Study
Design, Time of Data
Collection, Location
Study Groups n
(Males%) GDM Identification/Definition Treatment(s)
Target Blood Glucose Levels (BGLs)











NGT = 220 (54%)
GDM = 195 (51%)
At 26 to 28 weeks using National
Diabetes Data Group criteria
Diet only = 128
Diet + insulin = 67
Targeted fasting glucose >5.5
mmol/L and/or 2-h post-prandial
glucose >6.7 mmol/L.
Women maintained glucose values
within the target range with diet and




flank, thigh, abdominal SFT
FM: Significantly higher
(436 ± 206 vs. 362 ± 198, p = 0.0002)
%FM:
Significantly higher
(12.4 ± 4.6 vs. 10.4 ± 4.6, p = 0.0001)
SFT:
Significantly higher at all 5 sites
triceps (4.7 ± 1.1 vs. 4.2 ± 1.3, p = 0.0001)
subscapular (5.4 ± 1.4 vs. 4.6 ± 1.2, p = 0.0001)
flank (4.2 ± 1.2 vs. 3.8 ± 1.0, p = 0.0001)
thigh (6.0 ± 1.4 vs. 5.4 ± 1.5, p = 0.0001)





Hospital or Denver Health.
Colorado, USA [40]








using Carpenter and Coustan criteria
2 were diet control, 10 were
requiring insulin or
glyburide.
Not reported 1–3 weeks
ADP (Pea Pod)




14.7 ± 3.0 vs. 13.1 ± 5.0, p = 0.36
SFT:Significantly higher sum of SFT (11.7 ± 1.3 vs. 9.9 ±




Royal Brisbane and Women’s
Hospital
Queensland, Australia [21]
(additional data provided by
authors)
NGT = 77 (53%)
GDM = 84 (50%) ADIPS criteria
Dietary and physical
activity advice. Insulin
treatment was begun if
more than two glucose
measurements exceeded the
target range in 1 week.
Target BGLs were set
according to current ADIPS
guidelines: 5.5 mmol/L or lower
fasting, and 7.0 mmol/L or lower 2-h
post-prandial.
80% met both current fasting and
post-prandial ADIPS targets. 75%
met the lower targets of the
American Diabetes Association (5.3
and 6.7 mmol/L)
<6 days ADP (Pea Pod)
FM:
Significantly higher
(413 ± 192 vs. 350 ± 162, p = 0.003)
%FM:
Significantly higher




Royal Prince Alfred Hospital
Sydney, Australia [22]
NGT = 532 (53%)





could not be met.
Good glycaemic control was
achieved in 90% of women meeting
both fasting and post-prandial
ADIPS targets
<48 h ADP (Pea Pod)
%FM:
Not significantly different














All pregnant women had non-fasting
blood
glucose measured
regularly throughout pregnancy, and
women with an elevated
non-fasting glucose (>8 mmol/L)
underwent OGTT. GDM mothers
were identified based on the
European
Association for the Study of Diabetes
criteria, at 27 ± 7 gestational weeks.
All 26 received diet and
lifestyle advice, 4 received
insulin.




(640 ± 200 vs. 500 ± 230, p = 0.0034)
Obese group
Not significantly different sum of SFT




(16.44 ± 4.68 vs. 13.5 ± 4.6, p = 0.0036)
Obese group
Not significantly different sum of SFT (16.44 ± 4.68 vs.
15.23 ± 3.86, p = 0.26)
Studies are grouped according to the type of the outcome, and within these groups, the studies are subgrouped according to the body composition technique used. %FM: percent fat mass; ADP: air displacement
plethysmography; AGA: appropriate for gestational age; BMI: body mass index (kg/m2); FM: fat mass (g); GDM: gestational diabetes mellitus; IGDMtr: infants exposed to treated GDM; INGT: infants exposed to
NGT; LGA: large for gestational age; NGT: normal glucose tolerance; OGTT: oral glucose tolerance test; SFT: skinfold thickness (mm); TOBEC: total body electrical conductivity; *DIP: diabetes in pregnancy
(defined as diabetes first identified in pregnancy, but meeting glucose or HbA1c values diagnostic of overt diabetes outside pregnancy); ‡ body composition data for ‘treated GDM vs. NGT’ subgroup are
presented as IGDMtr vs. INGT.3.2.1. GDM screening criteria and target blood glucose concentrations.
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Eleven guidelines developed between 1964 and 2014 were used for screening and
diagnosing GDM by 22 studies (Table S1). The remaining three studies [20,33,47] used
centre-specific criteria for screening and diagnosing GDM. From the 25 studies, 24 used
an oral glucose tolerance test (OGTT) to diagnose GDM, and the other [17] used White’s
classification based on the age of onset and duration of diabetes. Commonly used crite-
ria included Carpenter and Coustan (1982), Australasian Diabetes in Pregnancy Society
(ADIPS, 1998), and the International Association of Diabetes and Pregnancy Study Groups
(IADPSG, 2011). Seven of the guidelines utilised a screening oral glucose challenge test
(OGCT) prior to an OGTT, while other guidelines used only a diagnostic OGTT. Only six of
the guidelines tested plasma glucose 3-h post OGCT. The cut-offs for fasting, 1-h, 2-h and
3-h blood glucose ranged between 5.0–7.0 mmol/L, 9.2–11.0 mmol/L, 8.0–9.1 mmol/L and
6.9–8.0 mmol/L, respectively. Seven GDM criteria required two or more abnormal values,
while three guidelines required only one abnormal value, for diagnosis of GDM.
Fasting and 2-h post-prandial plasma glucose targets for treated-GDM mothers dif-
fered between studies as follows; 5.0 mmol/L and 6.7 mmol/L [33,37], 5.3 mmol/L and
7.8 mmol/L [29], 5.3 mmol/L and 6.7 mmol/L [25,26], 5.5 mmol/L and 6.5 mmol/L [23],
5.5 mmol/L and 6.7 mmol/L [6,19], and 5.5 mmol/L and 7.0 mmol/L [11,12,20,24]. Two
studies [10,32] used HbA1c between 3.5–5.3% as the mean blood glucose target.
3.2.1. Treatments Used to Control GDM and Level of Glycaemic Control
Three studies [17,18,22] used ‘diet only’, and one study [23] used ‘insulin only’ to
treat GDM while others used combinations of treatments such as ‘diet with insulin if
required’ [10,11,19–21,26–29,31,33,37], ‘diet and exercise with insulin, if required’ [6,12,32,
34,36]. Metformin, alone or in combination with insulin, was used in two studies [24,35],
while glyburide alone or in combination with diet was used in another two studies [25,30].
Only 60% of the studies (n = 15) reported the level of glycaemic control in GDM women.
3.2.2. Adiposity Assessment Techniques Used in the Studies
Anthropometric and/or body composition information was available in 13 studies, in-
cluding air displacement plethysmography (ADP) [11,12,30,34], total body electrical conduc-
tivity (TOBEC) [6,21], or anthropometric equations proposed by Catalano et al. [10,27,35,37],
Dauncy et al. [17,29], and Weststrate and Deurenberg [31]. The most commonly assessed
individual SFT sites were triceps and subscapular, and four studies [17,31,33,37] presented
the sum of SFT at different sites (data of individual sites were not available).
3.3. Quality Assessment
Of the eight criteria listed in the Evidence Project risk of bias tool, two criteria, “(3)
pre-post intervention data”, and “(8) comparison groups equivalent at baseline on outcome
measures”, were not applicable for the studies selected for this review (Table 2). All selected
studies used non-probability sampling strategies (convenience or self-selected sampling);
thus, the criterion “random selection of participants for assessment” was not met by any of
them. All studies met the “control or comparison group” criterion. Nineteen studies [6,
11,17,19–21,24–29,31–37] met the criterion “cohort”, and except for 1 study [20], all others
met the criterion of “follow-up rate of 80% or more”. Only the three randomised control
trials (RCT) [24–26] included in the review met the criterion of “(4) random assignment of
participants to the intervention”. Results of the assessment of the criterion “(7) comparison
groups equivalent on sociodemographics” varied across the studies, with the following
outcomes: “Equivalent” [20,23,25,30], “Partially Equivalent” [6,21,22,24,26–29,32,34,36],
“Not Equivalent” [12,31,37], and “Not Reported” [10,11,17–19,33,35].
J. Clin. Med. 2021, 10, 835 11 of 20
Table 2. Quality assessment of the studies included in the review, using the Evidence Project risk of bias tool.
First Author Year






















Follow-Up Rate of 80% or More a
(7)







Judgement Judgement Judgement Judgement Judgement Judgement Follow-U p Rate Judgement Comment Judgement
Enzi 1980 Yes Yes No NA No Yes 87.5% NR NA
Stevenson 1991 No Yes No NA No NA NR NA
Vohr 1995 Yes Yes No NA No Yes 100% NR NA
Simmons 1997 Yes Yes No NA No No 57% Yes Ethnicity and sex not significantlydifferent NA
Okereke 2001 Yes Yes No NA No Yes 100% Partial Sex not significantly different,ethnicity significantly different NA
Catalano 2003 Yes Yes No NA No Yes 100% Partial Ethnicity significantly different,sex not significantly different NA
Ng 2004 No Yes No NA No NA Partial Sex not significantly different NA
Westgate 2006 No Yes No NA No NA Yes Sex and ethnicity not significantlydifferent NA
Rowan 2008 Yes Yes No Yes No Yes 97.6% Partial Ethnicity not significantly different NA
Lain 2009 Yes Yes No Yes No Yes 82.8% Yes NA
Landon 2009 Yes Yes No Yes No Yes 93.9% Partial Ethnicity not significantly different NA
Aman 2011 No Yes No NA No NA NR NA
Lingwood 2011 Yes Yes No NA No Yes 100% NR NA
Naf 2011 Yes Yes No NA No Yes 100% Partial Sex not significantly different NA
Schaefer-Graf 2011 Yes Yes No NA No Yes 100% Partial Sex not significantly different NA
Au 2012 No Yes No NA No NA No Significant difference in maternalethnicity NA
Buhling 2012 Yes Yes No NA No Yes 100% Partial Ethnicity not significantly different NA
Brumbaugh 2013 No Yes No NA No NA Yes Sex and ethnicity not significantlydifferent NA
Ubel 2014 Yes Yes No NA No Yes 100% No Sex significantly different NA
Mitanchez 2017 yes Yes No NA No Yes 90.3% NR NA
Kara 2017 Yes Yes No NA No Yes 100% Partial Sex not significantly different NA
Andersson-Hall 2018 Yes Yes No NA No Yes 83% Partial Sex not significantly different NA
Maple-Brown 2019 Yes Yes No NA No Yes 100% NR NA
Prentice 2019 Yes Yes No NA No NR Partial Sex not significantly different NA
Samsuddin 2020 Yes Yes No NA No Yes 100% No Ethnicity significantly different NA
NA: not applicable; NR: not reported. Studies are ordered according to the year of the publication. a Follow-up rate was calculated as the number of participants at the final assessment*100 divided by the
number of participants at the first assessment, as stated in the paper. b Infant sex and ethnicity were considered as sociodemographic characteristics. If the authors have only reported that the study arms are
equivalent on one of the sociodemographic characteristics, it was indicated as “Partial”, while if the study arms were not equivalent at least on one of the socio-demographics, it was decided that the criterion was
not met (“No”).
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3.4. Effects of Treatments for GDM on Infant Adiposity
3.4.1. Treated GDM vs. No Treatment for GDM
One RCT [36] investigated whether treatment for GDM normalised infant adiposity at
birth. In this study of 958 GDM women (485 treated vs. 473 no treatment), mean FM in
infants of GDM mothers who received the treatment of diet therapy (n = 427) and insulin,
if required (n = 36), was significantly lower (p = 0.003) than that of control infants whose
mothers received usual prenatal care (427 ± 198 g vs. 464 ± 222 g).
3.4.2. Different Treatment Regimens for GDM
Two studies [7,30] compared the effects of treating GDM with lifestyle modification
alone vs. lifestyle modification plus insulin, on infant birth measurements. A small
study [30] with a sample size of 20, found no significant differences in mean subscapular
SFT, between GDM exposed infants whose mothers were treated with ‘diet alone’ and
‘diet with insulin’. A comparatively larger study [7], with a sample size of 195, revealed
that compared to ‘diet and exercise only’, infants whose mothers were treated with ‘diet,
exercise and insulin’ had higher FM (492 ± 215 g vs. 407 ± 196 g, p = 0.006) and %BF
(13.6% ± 4.6% vs. 11.7 ± 4.5%, p = 0.007). These effects persisted even after adjusting for
gestational age, maternal pregravid weight and parity. Two RCTs [34,35] investigated the
difference in adiposity in infants of GDM mothers, who were treated with pharmacological
treatments for GDM. Rowan et al. [34] compared treating GDM women with metformin
(with supplemental insulin, if required, n = 363) to treatment with insulin alone (n = 370)
and reported that triceps (5.2 ± 1.6 vs. 5.1 ± 1.2, p = 0.30) and subscapular (5.2 ± 1.5 vs.
5.2 ± 1.3, p = 0.60) SFT (mm) were not significantly different between the groups. Lain
et al. [35] compared insulin (n = 41) with glyburide (n = 41), and found no significant
differences in mean triceps SFT (3.9 ± 0.7 vs. 3.9 ± 0.9, p = 0.89), subscapular SFT (4.1 ± 1.0
vs. 4.5 ± 1.3, p = 0.10), suprailiac SFT (2.1 ± 0.6 vs. 2.1 ± 0.6, p = 0.85), thigh SFT (5.1 ± 1.2
vs. 5.4 ± 1.7, p = 0.28), FM (370 ± 167 vs. 473 ± 278, p = 0.06) or %FM (11.2 ± 4.2 vs.
12.8 ± 5.7, p = 0.18). None of the studies compared ‘lifestyle modification alone’ with
‘pharmaceutical interventions’.
3.4.3. Treated GDM vs. NGT
Fat Mass (FM)
Ten studies [7,20,21,27,31,37,39,41,44,47] reported the effect of treated GDM compared
to NGT on infant FM. Overall, infants born to mothers with treated GDM (IGDMtr) had
significantly higher FM (mean difference, 95% confidence interval: 68.46 g, 29.91 to 107.01)
than infants born to NGT mothers (INGT); (Figure 2).
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Percent Fat Mass (%FM)
Nine studies [7,20–22,27,31,40,44,45] investigated the effect of treated GDM compared
to NGT on infant %FM. In the pooled result, %FM (1.98%, 0.54 to 3.42) in IGDMtr was
significantly higher than INGT (Figure 3).
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Skinfold Thickness (SFT)
The number of studies that reported SFT at individual skinfold sites were as follows:
triceps = 8 [7,20,28, 9,33,38,42,46]; subs apular = 7 [7,20,29,33,38,42,46]; flank = 3 [7,20,46];
an abdominal = 2 [7,29]. None of the comparis ns of skinfold sites were significantly
different between IGDMtr and INGT infants in the pooled results; triceps: 0.14 mm, −0.35
to 0.63 (Figure 4a); subscapular: 0.44 mm,−0.15 to 1.02 (Figure 4b); flank: 0.04 mm,−1.35 to
1.44 (Figure 4c) and abdominal: 0.33 mm, −0.06 to 0.72 (Figure 4d). Several other SFT sites,
i.e., biceps [42], quadriceps [46], suprailiac [29], iliac [38], femur [38], thigh [7] and calf [29],
were reported in single studies, and therefore, a meta-analysis could not be performed.
Four studies compared IGDMtr vs. INGT using sum of SFT at different body sites,
therefore they were not included in the meta-analysis. Of those, two reported that the
sum of SFT at ‘triceps and subscapular’ [40] and ‘subsca ular, subcostal, tricipital and
crural’ [27] was sig ificantly higher in IGDMtr. Another study [47] r ported that the sum
of SFT at ‘flank, triceps and subscapular’ was not significantly diff rent between IGDMtr
and INGT. A study [32] in which da a were not normally di tributed presented median
and interquartile range and reported that triceps (4.8 mm (4.2–5.1) vs. 4.7 mm (4.1–5.5))
and subscapular (4.8 mm (4.3–5.3) vs. 4.8 mm (4.1–5.3)) SFT were not significantly different
between the two infant groups.
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Heterogeneity between the Studies That Compared GDMtr vs. NGT
A high proportion of the ob erv d heteroge eity in all the meta-analyses (as indicated
by a I2 statistic > 90%) was due to underlying between-study differences [51]. We consid-
ered whether the GDM mothers achieved g od gl caemic control with the treatments as
one of the potential sources of heterogeneity. However, the information on the level of gly-
caemic control in GDM mothers was not reported in 40% of studies [27,30–33,38,40,43,45,46].
Therefore, the studies in which the authors stated that the mothers achieved good glycaemic
control were separated from other studies, to see if the achievement of good glycaemic
control mediated the relationship between GDM and infant adiposity. The test for subgroup
differences indicated that there was no statistically significant subgroup effect of studies
indicating GDM mothers achieving good glycaemic control on infant FM (p = 0.76), %FM
(p = 0.15), triceps (p = 0.34) and subscapular SFT (p = 0.73).
The test for subgroup di rences in ‘pre-2010′ vs. ‘post-2010′ studies showed a
statistically significant subgroup ffect on FM (p = 0.03, Figure S2) and %FM (p = 0.02,
Figure S3). Ther was no significant difference in FM and %FM between IGDMtr and
INGT in ‘post-2010′ studies, whereas, in ‘pre-2010′ studies, FM and %FM were significantly
higher in IGDMtr compared to their counterparts. Further, subgroup analyses by infant
body composition assessment technique were performed for infant FM and %FM. There
was no significant effect (p = 0.28) of body composition technique on infant FM (Figure S4).
Subgroup difference in %FM was significant (p < 0.00001); however, the number of studies
and participants who contributed to subgroups were considerably different (Figure S5).
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%FM measured with ADP (0.93%, −1.61 to 3.47) or the Catalano et al. equation (1.93%,
−0.56 to 4.43) did not significantly differ between IGDMtr and INGT. %FM measured by
TOBEC (2.13%, 1.34 to 2.93) or the Dauncy et al. equation (4.90%, 4.06 to 5.74) was higher
in IGDMtr. Leave-one-out sensitivity analysis demonstrated that removing the studies
that had used the Catalano equation or TOBEC changed the overall effect for %FM to
statistical non-significance. Of note, from the four studies that used ADP [21,22,40,44],
three [21,22,44] affirmed good glycaemic control in mothers. Sensitivity analysis performed
after removing the study [40] with no data on glycaemic control did not change the pooled
result for the ADP subgroup. Moreover, leave-one-GDM-criteria-out sensitivity testing
for FM and %FM did not show significant changes in the pooled effects. Specifically, the
sensitivity analysis for White’s classification, which is different from other criteria that
use an OGTT, did not significantly change the overall results for infant FM and %FM
(Figure S6).
4. Discussion
We performed a systematic review and a meta-analysis of published studies (irrespec-
tive of the study designs) reporting adiposity in infants exposed to GDM controlled with
therapeutic interventions. Treatments for GDM lowered newborn adiposity compared to
no treatment, and there were no significant differences in adiposity in IGDMtr according
to the mode of therapy; however, the evidence was insufficient due to the low number of
available studies. IGDMtr had higher FM and %FM compared to INGT, but there was no
significant difference in subcutaneous adiposity as measured by SFT.
Accelerated fat deposition in the foetus of GDM women can be reduced by strict
glycaemic control [36]. Most women with GDM can control blood glucose with lifestyle
changes such as diet modification, and increased physical activity; however, approximately
one-third of women may require additional pharmacological treatments [14]. Oral diabetic
medication is widely accepted by pregnant women in contrast to insulin because of easier
storage, administration and lower cost [52], but unlike insulin, both metformin and gly-
buride cross the placenta [53]. Additionally, meta-analyses of risks and benefits of using
insulin, metformin and glyburide in GDM women requiring drug treatment have shown
that glyburide is inferior to both insulin and metformin, resulting in higher birth weights
and increased risk of macrosomia, while metformin is associated with more preterm births
than insulin [54]. On the other hand, insulin can bind to its specific receptor (in the pla-
centa) to activate its signalling pathways; thus, insulin treatment still may have effects on
placental and foetal growth [55]. One of the studies included in our review [7] reported
that treatment with insulin in addition to lifestyle modification significantly increased the
FM and %FM in IGDMtr as opposed to lifestyle intervention alone; however, the authors
speculated that there might have been a confounding effect of other maternal factors as-
sociated with increased infant adiposity, as the former group of mothers (i.e., those who
also received insulin) were characterised with higher pre-pregnancy weight and parity
than their counterparts. Moreover, metformin and glyburide can impact foetal growth in
opposite ways [56,57]. Glyburide controls maternal hyperglycaemia by stimulating insulin
production. When glyburide is transported to the foetus through the placenta, it may also
increase insulin secretion by the foetal pancreas that results in foetal overgrowth [56]. On
the other hand, metformin inhibits glucose and amino acid transportation from the mother
to the developing foetus through the placenta [57], which may cause foetal undergrowth.
Despite this, the findings of the two RCTs included in our review [34,35] suggested that the
effects of metformin, glyburide or insulin on infant adiposity were not significantly differ-
ent; nonetheless, more studies are required for definitive conclusions. As reported in two
recent systematic reviews, although there are no significant differences in body composition
at birth [58], children exposed to metformin in utero show accelerated postnatal growth,
compared to those exposed to insulin [59]. Therefore, tracking body composition trajectory
of children exposed to pharmacological interventions in utero should be a research priority.
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Our meta-analysis shows that treatments for GDM normalise newborns’ subcutaneous
fat measured by SFT, but not overall adiposity measured by FM and %FM. These findings
suggest that the phenotype of the IGDMtr may be distinguished with increased internal adi-
posity. Increased intra-abdominal adiposity is associated with several metabolic disorders,
while superficial subcutaneous adiposity may exert a protective effect [60]. Furthermore,
exposure to excess fuels in the gestational environment may lead to increased hepatic fat
deposition in the foetus, which possibly plays a role in the development of nonalcoholic
liver disease in children [61]. On the other hand, the accuracy of SFT measurements is
dependent on the skills of the measurer, and the adiposity prediction equations with SFT
are highly specific to the infant population that the data were derived from [62]. Thus,
differentiating adipose tissue compartments with more reliable objective techniques and
assessing hepatic fat deposition in IGDMtr and INGT at birth is important to identify these
differences and any effects of GDM treatments. Comparing different adiposity compart-
ments was beyond the scope of the current review, and such studies are very limited. Two
small studies [40,63] reported that there were no significant differences in %FM, subcu-
taneous fat (cm3) and intra-abdominal fat/length (cm2) at 1–3 weeks [40], and in total
adipose tissue (cm3), subcutaneous adipose tissue (cm3), internal abdominal adipose tissue
(cm3) at 1–2 weeks [63] in IGDMtr and INGT infants. Intriguingly, one study reported a
significant increase in intrahepatocellular lipid content in IGDMtr compared to INGT, while
the other did not detect such a difference. However, glycaemic control was not described in
the former study, whereas ~80% of mothers in the latter study had good glycaemic control
with a mean third-trimester HbA1c level of 5.3%.
There were no significant differences in %FM in IGDMtr and INGT in studies ‘post-
2010′ or when newborn overall adiposity was measured with ADP. These findings may
be attributed to more intensive management of hyperglycaemia in the ‘post-2010′ period.
Moreover, our findings highlight the importance of using more accurate and reliable objec-
tive infant body composition techniques such as ADP. The high degree of between-study
heterogeneity may have arisen from the use of a wide variety of GDM diagnostic criteria,
differences in the severity of hyperglycemia and level of glycaemic control, and confound-
ing effects of maternal obesity, ethnicity, gestational weight gain, smoking, gestational age,
infants’ sex and age at the investigation. Future studies should adopt universal criteria
for the diagnosis of GDM, use reliable body composition assessment techniques such as
ADP, and report the treatments and level of glycaemic control in GDM mothers through-
out the pregnancy to enable robust conclusions on the association between GDM and
newborn adiposity.
To our knowledge, the current review is the first to simultaneously evaluate studies
reporting adiposity in newborns exposed to treated GDM vs. no treatment, different
treatment regimens for GDM, and treated GDM vs. NGT. Adiposity in infants exposed
to GDM compared to NGT has been investigated in a subgroup analysis of a previous
systematic review [64] that examined the literature focused on the effect of all types of
maternal diabetes. The authors found higher FM, %FM, triceps SFT and subscapular SFT in
GDM-exposed infants compared to NGT; however, in some of the studies included in their
meta-analysis (e.g., HAPO Study [11]), mothers were not treated. Other strengths of our
study include the search of the literature in five major databases, investigation of differences
in SFT sites such as abdominal and flank regions in addition to commonly reported triceps
and subscapular measures, and investigation of potential sources of heterogeneity via
subgroup and sensitivity analyses. Limitations of our study were that we only included
studies published in English, excluded studies in which GDM status was self-reported by
mothers where no information was reported on the use of treatments for glycaemic control,
and considered only the most common measures of adiposity, i.e., FM, %FM and SFT, for
comparison purposes.
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5. Conclusions
Irrespective of the therapeutic strategy, treatment for GDM appears to reduce excess
adiposity characteristic for newborns exposed to untreated GDM, but the evidence is
limited. Due to the potential effects of oral hypoglycaemic medications on foetal growth,
further studies on the impact of different GDM therapies on newborn adiposity are also
warranted. Despite the significant heterogeneity found between the studies, our meta-
analysis revealed higher overall adiposity (as measured with FM and %FM) but similar
subcutaneous adiposity (as measured with SFT) in IGDMtr compared to INGT, suggesting
that higher adiposity in IGDMtr may be due to excess fat accrual in internal adipose tissue.
Future studies should distinguish adipose tissue distribution of IGDMtr and INGT with
sufficient power to confirm these differences.
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